Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,024.00
Bid: 12,024.00
Ask: 12,028.00
Change: 36.00 (0.30%)
Spread: 4.00 (0.033%)
Open: 12,254.00
High: 12,256.00
Low: 12,018.00
Prev. Close: 11,988.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - [AstraZeneca Plc]

22 May 2014 15:16

RNS Number : 8533H
Viking Global Investors LP
22 May 2014
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Identity of the person whose positions/dealings are being disclosed:

Viking Global Investors LP

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient

n/a

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

AstraZeneca Plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

n/a

(e) Date position held/dealing undertaken:

21 May 2014

(f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?

NO

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

USD 0.25 ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0

0

0

(2) Derivatives (other than options):

19,602,422

1.55

0

0

(3) Options and agreements to purchase/sell:

0

0

0

0

 

TOTAL:

19,602,422

1.55

0

0

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

 

 

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

USD 0.25 ordinary

CFD

 

Reducing a long position

123,000

GBP 44.39500

USD 0.25 ordinary

CFD

 

Reducing a long position

115,600

GBP 44.34500

USD 0.25 ordinary

CFD

 

Reducing a long position

120,000

GBP 44.22074

USD 0.25 ordinary

CFD

 

Reducing a long position

64,800

GBP 44.20000

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

22 May 2014

Contact name:

Daniel Taub

Telephone number:

203-863-5000

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RETPGUAGAUPCGCP
Date   Source Headline
24th Mar 20226:00 pmRNSEvusheld Positive EU CHMP Opinion
24th Mar 20227:00 amRNSUpdate on CALLA Phase III trial for Imfinzi
23rd Mar 202211:00 amRNSNotice of AGM
17th Mar 20227:00 amRNSSettlement of patent litigation for Ultomiris
14th Mar 20227:05 amRNSLynparza approved in US for early breast cancer
14th Mar 20227:00 amRNSUpdate on US review of Fasenra in nasal polyps
9th Mar 20223:30 pmRNSDirector/PDMR Shareholding
7th Mar 20223:30 pmRNSDirector/PDMR Shareholding
1st Mar 20223:30 pmRNSDirector/PDMR Shareholding
1st Mar 20223:00 pmRNSTotal Voting Rights
1st Mar 20227:00 amRNSAstraZeneca and Neurimmune close deal for NI006
23rd Feb 20227:00 amRNSFiling of Form 20-F with SEC
22nd Feb 202211:00 amRNSChair succession planning update and Annual Report
21st Feb 20227:00 amRNSEnhertu improves PFS and OS in HER2-low BC
16th Feb 20227:00 amRNSSaphnelo approved in EU for SLE
15th Feb 20227:00 amRNSLynparza combo delays progression risk in prostate
11th Feb 20223:30 pmRNSDirector/PDMR Shareholding
10th Feb 20227:00 amRNSAZN: Full year and Q4 2021 results
1st Feb 20223:00 pmRNSTotal Voting Rights
19th Jan 20227:05 amRNSImfinzi improves survival in biliary tract cancer
19th Jan 20227:00 amRNSImfinzi combo shows unprecedented survival in HCC
17th Jan 20227:00 amRNSEnhertu granted Priority Review for breast cancer
7th Jan 20227:00 amRNSAstraZeneca and Neurimmune sign deal for NI006
5th Jan 20227:00 amRNSTransfer of rights to Eklira, Duaklir completed
4th Jan 20223:00 pmRNSTotal Voting Rights
29th Dec 20217:00 amRNSAstraZeneca and Ionis close eplontersen deal
21st Dec 20217:00 amRNSUltomiris accepted for FDA Priority Review for gMG
20th Dec 20217:05 amRNSTezspire approved in the US for severe asthma
20th Dec 20217:00 amRNSSaphnelo recommended for EU approval for SLE
15th Dec 20213:00 pmRNSDirector/PDMR Shareholding
9th Dec 20217:00 amRNSEvusheld US FDA EUA
7th Dec 20217:00 amRNSAstraZeneca, Ionis to collaborate on eplontersen
1st Dec 20213:00 pmRNSBlock listing Interim Review
1st Dec 20213:00 pmRNSTotal Voting Rights
30th Nov 20217:00 amRNSLynparza granted FDA Priority Review for OlympiA
15th Nov 20214:00 pmRNSDirector/PDMR Shareholding
12th Nov 20217:00 amRNSAZN: Year to date and Q3 2021 results
1st Nov 20213:00 pmRNSTotal Voting Rights
1st Nov 20217:00 amRNSAstraZeneca to transfer rights to Eklira, Duaklir
25th Oct 20217:00 amRNSImfinzi improved survival in biliary tract cancer
18th Oct 20217:00 amRNSAZ recommends ADS holders reject mini-tender offer
15th Oct 20217:00 amRNSImfinzi & tremelimumab improved OS in liver cancer
11th Oct 20217:00 amRNSAZD7442 PhIII trial positive in COVID outpatients
4th Oct 20217:00 amRNSEnhertu granted BTD for breast cancer
1st Oct 20213:00 pmRNSTotal Voting Rights
30th Sep 20214:00 pmRNSDirector/PDMR Shareholding
29th Sep 20217:00 amRNSAstraZeneca to fully acquire Caelum Biosciences
28th Sep 20217:00 amRNSSaphnelo approved in Japan for SLE
24th Sep 20217:00 amRNSLynparza PROpel trial meets primary endpoint
23rd Sep 20217:00 amRNSBoard Committee Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.